The role of rifaximin in the treatment and chemoprophylaxis of travelers' diarrhea

Therapeutics and Clinical Risk Management

Volumn 5, Issue 1, 2009, Pages 841-848

  Koo, Hoonmo L ^a,b   DuPont, Herbert L ^a,b   Huang, David B ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Prevention; Rifaximin; Travelers' diarrhea; Treatment

Indexed keywords

AZITHROMYCIN; CIPROFLOXACIN; COTRIMOXAZOLE; LEVOFLOXACIN; LOPERAMIDE; MIDAZOLAM; NORGESTIMATE; PLACEBO; RIFAXIMIN;

ABDOMINAL PAIN; AREA UNDER THE CURVE; CAMPYLOBACTER JEJUNI; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; ESCHERICHIA COLI; FECES INCONTINENCE; FLATULENCE; FOOD CONTAMINATION; HUMAN; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; NAUSEA; RECOMMENDED DRUG DOSE; REVIEW; SALMONELLA; SHIGELLA FLEXNERI; SINGLE DRUG DOSE; TENESMUS; TRAVELLER DIARRHEA;

EID: 77949441303     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. DuPont HL. New insights and directions in travelers' diarrhea. Gastroenterol Clin North Am. 2006;35:337-353.
2. Adachi JA, Mathewson JJ, Jiang ZD, Ericsson CD, DuPont HL. Enteric pathogens in Mexican sauces of popular restaurants in Guadalajara, Mexico, and Houston, Texas. Ann Intern Med. 2002;136:884-887.
3. Jiang ZD, Lowe B, Verenkar MP, et al. Prevalence of enteric pathogens among international travelers with diarrhea acquired in Kenya (Mombasa), India (Goa), or Jamaica (Montego Bay). J Infect Dis. 2002;185:497-502.
4. DuPont HL, Haake R, Taylor DN, et al. Rifaximin treatment of pathogen-negative travelers' diarrhea. J Travel Med. 2007;14:16-19.
5. Okhuysen PC, Jiang ZD, Carlin L, Forbes C, DuPont HL. Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am J Gastroenterol. 2004;99: 1774-1778.
6. Dworkin MS, Shoemaker PC, Goldoft MJ, Kobayashi JM. Reactive arthritis and Reiter's syndrome following an outbreak of gastroenteritis caused by Salmonella enteritidis. Clin Infect Dis. 2001;33: 1010-1014.
7. Rees JH, Soudain SE, Gregson NA, Hughes RA. Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med. 1995; 333:1374-1379.
8. Xifaxan (rifaximin) tablets [prescribing information]. Palo Alto, CA: Salix Pharmaceuticals, 2008.
9. Jiang ZD, Ke S, Palazzini E, Riopel L, DuPont H. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother. 2000;44:2205-2206.
10. Descombe JJ, Dubourg D, Picard M, Palazzini E. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res. 1994;14:51-56.
11. Gionchetti P, Rizello F, Ferrieri A, et al. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dig Dis Sci. 1999;44: 1220-1221.
12. Rizzello F, Rionchetti P, Venturi A, et al. Rifaximin systemic absorption in patients with ulcerative colitis. Eur J Clin Pharmacol. 1998;54: 91-93.
13. Pentikis HS, Connolly M, Trapnell CB, et al. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers. Pharmacotherapy. 2007;27: 1361-1369.
14. Trapnell CB, Connolly M, Pentekis H, et al. The absence of effect of oral rifaximin administration on the pharmacokinetics of ethinyl estradiol and norgestimate contraceptive combination in healthy female volunteers. Ann Pharmacother. 2007;41:222-228.
15. Gomi H, Jiang Z, Adachi JA, et al. In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler's diarrhea in four geographic regions. Antimicrob Agents Chemother. 2001; 45:212-216.
16. Ruiz J, Mensa L, O'Callaghan C, et al. In vitro antimicrobial activity of rifaximin against enteropathogens causing traveler's diarrhea. Diagn Microbiol Infect Dis. 2007;59:473-475.
17. Sierra JM, Navia MM, Vargas M, et al. In vitro activity of rifaximin against bacterial enteropathogens causing diarrhoea in children under 5 years of age in Ifakara, Tanzania. J Antimicrob Chemother. 2001;47:904-905.
18. Sierra JM, Ruiz J, Navia MM, Vargas M, Vila J. In vitro activity of rifaximin against enteropathogens producing traveler's diarrhea. Antimicrob Agents Chemother. 2001;45:643-644.
19. Ruiz J, Mensa L, Pons MJ, Vila J, Gascon J. Development of Escherichia coli rifaximin-resistant mutants: frequency of selection and stability. J Antimicrob Chemother. 2008;61:1016-1019.
20. Vitali B, Turroni S, Dal Piaz F, et al. Genetic and proteomic characterization of rifaximin resistance in Bifidobacterium infantis BI07. Res Microbiol. 2007;158:355-362.
21. O'Connor JR, Galang MA, Sambol SP, et al. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother. 2008;52:2813-2817.
22. Soro O, Pesce A, Raggi M, et al. Selection of rifampicin-resistant Mycobacterium tuberculosis does not occur in the presence of low concentrations of rifaximin. Clin Microbiol Infect. 1998;3:147-151.
23. Malvisi Stracciari J, Venturini AP, Anfossi P, et al. Sensitivity to rifaximin and rifampicin of Mycobacterium tuberculosis isolated from guinea pigs treated orally with rifaximin. Chemioterapia. 1987;6:82-84.
24. DuPont HL, Jiang ZD, Okhuysen PC, et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann Intern Med. 2005;142:805-812.
25. DuPont HL, Ericsson CD, Mathewson JJ, et al. Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers' diarrhea. Digestion. 1998;59:708-714.
26. Kassenborg HD, Smith KE, Vugia DJ, et al; Emerging Infections Program FoodNet Working Group. Fluoroquinolone-resistant Campylobacter infections: eating poultry outside of the home and foreign travel are risk factors. Clin Infect Dis. 2004;38: S279-S284.
27. Kuschner RA, Trofa AF, Thomas RJ, et al. Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. Clin Infect Dis. 1995;2:536-541.
28. DuPont HL, Jiang ZD, Ericsson CD, et al. Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis. 2001;33:1807-1815.
29. Taylor DN, Bourgeois AL, Ericsson CD, et al. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. Am J Trop Med Hyg. 2006;74:1060-1066.
30. Steffen R, Sack DA, Riopel L, et al. Therapy of travelers' diarrhea with rifaximin on various continents. Am J Gastroenterol. 2003;98: 1073-1078.
31. DuPont HL, Jiang ZD, Belkind-Gerson J, et al. Treatment of travelers' diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone. Clin Gastroenterol Hepatol. 2007;5:451-456.
32. Taylor DN, McKenzie R, Durbin A, Carpenter C, Haake R, Bourgeois AL. Systemic pharmacokinetics of rifaximin in volunteers with shigellosis. Antimicrob Agents Chemother. 2008;52:1179-1181.
33. Hoge CW, Gambet JM, Srijan A, Pitarangsi C, Echeverria P. Trends in antibiotic resistance among diarrhea pathogens isolated in Thailand over 15 years. Clin Infect Dis. 1998;26:341-345.
34. Adachi JA, Ericsson CD, Jiang ZD, et al. Azithromycin found to be comparable to levofloxacin for the treatment of US travelers with acute diarrhea acquired in Mexico. Clin Infect Dis. 2003;37:1165-1171.
35. Sack RB. Prophylactic antimicrobials for traveler's diarrhea: an early history. Clin Infect Dis. 2005;41:S553-S556.
36. Travelers' diarrhea: National Institutes of Health Consensus Development Conference. Bethesda, Maryland, January 28-30, 1985. Rev Infect Dis. 1986;8:S109-S233.
37. Gwee KA, Graham JC, McKendrick MW, et al. Psychometric scores and persistence of irritable bowel after infectious diarrhoea. Lancet. 1996;347:150-153.
38. DuPont HL, Ericsson CD, de la Cabada FJ, et al. Prevention of travelers' diarrhea with rifaximin - a phase 3 randomized double-blind placebo-controlled trial in U.S. students in Mexico. Am J Gastroenterol. 2006;101:S197.
39. DuPont HL. Systematic review: prevention of travellers' diarrhoea. Aliment Pharmacol Ther. 2008;27:741-751.
40. Taylor DN, McKenzie R, Durbin A, et al. Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge. Clin Infect Dis. 2006;42:1283-1288.
41. Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. Rifaximin improves the symptoms of irritable bowel syndrome: A randomized trial. Ann Intern Med. 2006:145;557-563.
42. Majewski M, McCallum RW. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial. Adv Med Sci. 2007;52:139-142.
43. Lembo AJ. Rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: short term treatment leading to long term sustained response, efficacy of co-primary endpoints: adequate relief/control of global IBS symptoms and IBS-associated bloating [abstract]. San Diego, CA: Digestive Disease Week; 2008.
44. Mas A, Rodes J, Sunyer L, et al; the Spanish Association for the Study of the Liver Hepatic Encephalopathy Cooperative Group. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized double-blind, double-dummy, controlled clinical trial. J Hepatol. 2003;38:51-58.
45. Williams R, James OF, Warnes TW, et al. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study. Eur J Gastroenterol Hepatol. 2000;12:203-208.
46. Lauritano C, Gabrielli M, Lupascu A, et al. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2005;22:31-35.
47. Majewski M, Reddymasu SC, Sostarich S, et al. Efficacy of rifaximin, a nonabsorbed oral antibiotic, in the treatment of small intestinal bacterial overgrowth. Am J Med Sci. 2007;333:266-270.
48. Johnson S, Schriever C, Galang M, Kelly CP, Gerding DN. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis. 2007;44:846-848.
49. Garey KW, Jiang ZD, Bellard A, DuPont HL. Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: An uncontrolled pilot study. J Clin Gastroenterol. 2008 Apr 1 [Epub ahead of print].
50. Papi C, Ciaco A, Koch M, et al. Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial. Aliment Pharmacol Ther. 1995;9:33-39.
51. Colecchia A, Vestito A, Pasqui F, et al. Efficacy of long term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated colonic diverticular disease. World J Gastroenterol. 2007;13:264-269.
52. Prantera C, Lochs H, Campieri M, et al. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther. 2006;23:1117-1125.
53. Shafran I JL. An open-label evaluation of rifixamin in the treatment of Crohn's disease. Curr Med Res Opin. 2005;21:1165-1169.
54. Isaacs KL, Sandler RS, Abreu M, et al; Crohn's and Colitis Foundation of American Clinical Alliance. Rifaximin for the treatment of pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2007;13:1250-1255.
55. Abdelrazeq AS, Lund JN, Kelley SM, Leveson SH. Rifaxaminciprofloxacin combination therapy is effective in patients with chronic, active, refractory pouchitis. Colorectal Dis. 2005;7:182-186.
56. Verardi S, Varardi V, Fusillo M. Rifaximin effectiveness evaluation in the preparation of large intestine to surgery. Eur Rev Med Pharmacol Sci. 1986;8:267-270.
57. Scalco GB, Rossi MR, Rubbini M, Cirelli C. Rifaximin: a new rifamycin for the prophylaxis of the septic complications in the large bowel surgery. Policlinico Sez Chir. 1987;94:41-45.